Action on Hearing Loss Logo
    Total results:
    Search
      Total results:

      NICE publishes new guideline on hearing loss

      The National Institute for Health and Care Excellence (NICE) has published a new guideline for the assessment and management of hearing loss in adults for the first time!

      By: Gemma Twitchen | 21 June 2018

      In 2015, Action on Hearing Loss lobbied for the publication of this guideline and acted as a key stakeholder in its initial development. We also responded to NICE’s consultation on the draft version in January. The final version of the guideline titled ‘Hearing Loss: Assessment and Management’ has now been released, and is available to read here.

      The NICE guideline has been produced by a committee of experts in hearing loss, and consists of recommendations on how to best identify, refer, diagnose, treat and manage patients based on the best evidence available. The guideline officially only covers England. Decisions on how they apply to Wales, Scotland and Northern Ireland are made by the devolved administrators, who are often involved and consulted with in the development process.

      The publication of the NICE guideline reflects the national priority to tackle the growing public health challenge of hearing loss. It is a vitally important document which will further strengthen the case for the prevention and management of hearing loss. And enable providers and commissioners to recognise the impact of hearing loss on individuals, and the economic burden that unaddressed hearing loss places on the health and social care system.

      The guideline makes a number of recommendations which run contrary to proposals to restrict hearing aid provision made by several CCGs across the country in recent years. A key recommendation is that the provision of hearing aids should be based on need rather than on hearing thresholds. The guideline states that descriptors such as ‘mild’, ‘moderate’, ‘severe’ or ‘profound’ should not be used as the sole determinant for the provision of hearing support, since this is not a reliable indicator of the difficulty experienced with communication and impact of hearing loss on day to day to life.

      The guideline also highlights the cost effectiveness of hearing aids. Stating that fitting hearing aids would be highly cost-effective compared to no treatment at the NICE cost-effectiveness threshold. It also recognises the association between hearing loss and dementia, and recommends referring adults with diagnosed or suspected dementia for hearing assessment.

      Health and care professionals are also recommended to provide adults with hearing loss information about assistive listening devices and organisations which can provide advice on how to obtain them. Recommendations are also set out on the removal of ear wax in primary and community care.

      When put into practice, NICE guidelines have the potential to effectively target health and care resources to significantly improve patient outcomes, in line with the best evidence available of clinical and cost-effectiveness. The publication of the NICE guideline on hearing loss comes at a critical time when we have seen budget cuts to audiology services and proposals to cut the provision of hearing aids across the country. The challenge which lies ahead now is ensuring that the guideline is implemented by health and social care practitioners and commissioners.

      We will be working closely with NICE to promote and support the implementation of the NICE guideline to achieve better outcomes for patients, and reductions in local variation in access and quality of care across the UK.

      Read the guideline 'Hearing Loss:Assessment and Management' here.

      You can also read more about NICE here.

      About NICE

      About NICE

      Recent Posts

      EE partnership brings unbeatable packages

      For the first time ever, selected mobile phones with EE Pay As You Go plans, tailored for people who are deaf or have hearing loss, are available from Action on Hearing Loss.

      By: Brian Burns
      17 October 2018

      REGAIN update on the progress so far and a further opportunity for people with hearing loss to take part in the trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).

      By: REGAIN
      16 October 2018

      Preventing hearing loss: the search for treatments

      Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.

      By: Dr Carina Santos
      12 October 2018

      Shining a light on the cochlea

      We fund research across the globe into treatments for hearing loss and tinnitus. One of our newest projects, at the Bionics Institute in Australia, is investigating if we can improve how well cochlear implants work using light.

      By: Dr Tracey Pollard
      11 October 2018

      Recent Posts

      EE partnership brings unbeatable packages

      For the first time ever, selected mobile phones with EE Pay As You Go plans, tailored for people who are deaf or have hearing loss, are available from Action on Hearing Loss.

      By: Brian Burns
      17 October 2018

      REGAIN update on the progress so far and a further opportunity for people with hearing loss to take part in the trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).

      By: REGAIN
      16 October 2018

      Preventing hearing loss: the search for treatments

      Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.

      By: Dr Carina Santos
      12 October 2018

      Shining a light on the cochlea

      We fund research across the globe into treatments for hearing loss and tinnitus. One of our newest projects, at the Bionics Institute in Australia, is investigating if we can improve how well cochlear implants work using light.

      By: Dr Tracey Pollard
      11 October 2018